Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple Sclerosis

[1]  Y. Haberman,et al.  A key requirement for CD300f in innate immune responses of eosinophils in colitis , 2016, Mucosal Immunology.

[2]  J. Coligan,et al.  Enhanced efferocytosis by dendritic cells underlies memory T-cell expansion and susceptibility to autoimmune disease in CD300f-deficient mice , 2016, Cell Death and Differentiation.

[3]  N. Lago,et al.  CD300f immunoreceptor contributes to peripheral nerve regeneration by the modulation of macrophage inflammatory phenotype , 2015, Journal of Neuroinflammation.

[4]  E. Noguchi,et al.  Identification and Characterization of CD300H, a New Member of the Human CD300 Immunoreceptor Family* , 2015, The Journal of Biological Chemistry.

[5]  J. Coligan,et al.  CD300f associates with IL-4 receptor α and amplifies IL-4–induced immune cell responses , 2015, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Michael J E Sternberg,et al.  The Phyre2 web portal for protein modeling, prediction and analysis , 2015, Nature Protocols.

[7]  S. Schwartz,et al.  The Receptor CMRF35-Like Molecule-1 (CLM-1) Enhances the Production of LPS-Induced Pro-Inflammatory Mediators during Microglial Activation , 2015, PloS one.

[8]  J. Coligan,et al.  CD300b regulates the phagocytosis of apoptotic cells via phosphatidylserine recognition , 2014, Cell Death and Differentiation.

[9]  J. Coligan,et al.  p85α recruitment by the CD300f phosphatidylserine receptor mediates apoptotic cell clearance required for autoimmunity suppression , 2014, Nature Communications.

[10]  F. Borrego.  The CD300 molecules: an emerging family of regulators of the immune system. , 2013, Blood.

[11]  T. Abe,et al.  The receptor LMIR3 negatively regulates mast cell activation and allergic responses by binding to extracellular ceramide. , 2012, Immunity.

[12]  N. Lago,et al.  Overexpression of the Immunoreceptor CD300f Has a Neuroprotective Role in a Model of Acute Brain Injury , 2012, Brain pathology.

[13]  J. Andersen,et al.  Human CD300a binds to phosphatidylethanolamine and phosphatidylserine, and modulates the phagocytosis of dead cells. , 2012, Blood.

[14]  S. Schwartz,et al.  Cloning and Characterization of CD300d, a Novel Member of the Human CD300 Family of Immune Receptors* , 2012, The Journal of Biological Chemistry.

[15]  S. Honda,et al.  Identification of phosphatidylserine as a ligand for the CD300a immunoreceptor. , 2012, Biochemical and biophysical research communications.

[16]  J. Coligan,et al.  Cutting Edge: Mouse CD300f (CMRF-35–Like Molecule-1) Recognizes Outer Membrane-Exposed Phosphatidylserine and Can Promote Phagocytosis , 2011, The Journal of Immunology.

[17]  S. Schwartz,et al.  CD300 Heterocomplexes, a New and Family-restricted Mechanism for Myeloid Cell Signaling Regulation* , 2010, The Journal of Biological Chemistry.

[18]  T. Abe,et al.  TIM1 is an endogenous ligand for LMIR5/CD300b: LMIR5 deficiency ameliorates mouse kidney ischemia/reperfusion injury , 2010, The Journal of experimental medicine.

[19]  Michael J. E. Sternberg,et al.  3DLigandSite: predicting ligand-binding sites using similar structures , 2010, Nucleic Acids Res..

[20]  M. van Lookeren Campagne,et al.  Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1 , 2010, The Journal of experimental medicine.

[21]  C. Pace,et al.  Increasing protein stability by improving beta‐turns , 2009, Proteins.

[22]  Yutaka Enomoto,et al.  An Activating and Inhibitory Signal from an Inhibitory Receptor LMIR3/CLM-1: LMIR3 Augments Lipopolysaccharide Response through Association with FcRγ in Mast Cells1 , 2009, The Journal of Immunology.

[23]  Dietmar Schomburg,et al.  Computational modeling of protein mutant stability: analysis and optimization of statistical potentials and structural features reveal insights into prediction model development , 2007, BMC Structural Biology.

[24]  M. López-Botet,et al.  The IREM-1 (CD300f) Inhibitory Receptor Associates with the p85α Subunit of Phosphoinositide 3-Kinase1 , 2007, The Journal of Immunology.

[25]  J. Marquez,et al.  The crystal structure of the extracellular domain of the inhibitor receptor expressed on myeloid cells IREM-1. , 2006, Journal of molecular biology.

[26]  Águeda Martínez-Barriocanal,et al.  Molecular and Functional Characterization of CD300b, a New Activating Immunoglobulin Receptor Able to Transduce Signals through Two Different Pathways1 , 2006, The Journal of Immunology.

[27]  H. Aguilar,et al.  IREM‐1 is a novel inhibitory receptor expressed by myeloid cells , 2004, European journal of immunology.

[28]  A. Órfão,et al.  Molecular Characterization of a Novel Immune Receptor Restricted to the Monocytic Lineage1 , 2004, The Journal of Immunology.

[29]  W. Seaman,et al.  CMRF-35-Like Molecule-1, a Novel Mouse Myeloid Receptor, Can Inhibit Osteoclast Formation1 , 2003, The Journal of Immunology.

[30]  R. Biassoni,et al.  Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells , 1999, European journal of immunology.

[31]  Y. Alon,et al.  CD300fはIL‐4受容体αと会合してIL‐4誘導免疫細胞応答を増幅する , 2015 .

[32]  T. Kitamura,et al.  Sphingomyelin and ceramide are physiological ligands for human LMIR3/CD300f, inhibiting FcεRI-mediated mast cell activation. , 2014, The Journal of allergy and clinical immunology.

[33]  F. Quintana,et al.  [Immunopathology of multiple sclerosis]. , 2014, Medicina.

[34]  J. Cannon,et al.  Specific lipid recognition is a general feature of CD300 and TREM molecules , 2011, Immunogenetics.